person · Reporting owner
Marshall William Stuart
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Viridian Therapeutics, Inc.\DE
Report date October 15, 2020 · Filed January 15, 2021
Section 16 reporting ended · disclosed 2021-01-15. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2020 Filed Feb 14, 2020 18:18 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 464,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-20-009783 · doc4.xml · derivative · entry 1 Marshall William Stuart · CIK 0001693127 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,000 Underlying: Common Stock · 464,000 shares Expires 2030-02-11 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). The shares shall vest as follows: (i) 50% shall vest in 48 equal monthly installments beginning on March 12, 2020, (ii) 25% shall vest on completion of a specified milestone related to cobomarsen development and (iii) 25% shall vest on completion of a specified milestone related to MRG-229 development, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
| August 21, 2019 Filed Feb 13, 2020 18:58 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantCommon Stock | 1,250 | $1.14 | $1,423.75 |
DisclosureSEC source: 0001209191-20-009420 · doc5.xml · nonDerivative · entry 2 Marshall William Stuart · CIK 0001693127 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,646 F1 · kind: These shares were acquired under the Miragen Therapeutics, Inc. 2016 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 21, 2019 Filed Feb 13, 2020 18:58 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantCommon Stock | 1,250 | $2.46 | $3,070.63 |
DisclosureSEC source: 0001209191-20-009420 · doc5.xml · nonDerivative · entry 1 Marshall William Stuart · CIK 0001693127 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,396 F1 · kind: These shares were acquired under the Miragen Therapeutics, Inc. 2016 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:25 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 232,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001209191-19-008515 · doc4.xml · derivative · entry 1 Marshall William Stuart · CIK 0001693127 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,000 Underlying: Common Stock · 232,000 shares Expires 2029-02-05 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on May 7, 2019 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 16:36 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | Exercise / conversionStock Option (right to buy) · Derivative | 115,818 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001209191-18-010428 · doc4.xml · derivative · entry 2 Marshall William Stuart · CIK 0001693127 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,818 shares Expires 2018-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. The option expires ten years after the date of grant. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 16:36 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | Exercise / conversionCommon Stock | 115,818 | $0.57 | $66,016.26 |
DisclosureSEC source: 0001209191-18-010428 · doc4.xml · nonDerivative · entry 1 Marshall William Stuart · CIK 0001693127 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This filing relates to the exercise of vested options to purchase the Issuer's common stock granted to the Reporting Person under one of the Issuer's equity incentive plans. None of the shares of common stock received upon exercise of the option were sold by the Reporting Person and all such shares are subject to a lock-up agreement between the Reporting Person and certain underwriters. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:11 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 245,000 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-18-007256 · doc4.xml · derivative · entry 1 Marshall William Stuart · CIK 0001693127 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 245,000 shares Expires 2028-01-30 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on April 30, 2018 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 20:23 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $11.01 | $0.00 |
DisclosureSEC source: 0001209191-17-011777 · doc4.xml · derivative · entry 1 Marshall William Stuart · CIK 0001693127 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). The shares vest in 48 equal monthly installments beginning on February 16, 2017, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.